

Study Number: IMM20704

Test Type: TOX

Route: Oral Gavage

Species/Strain: Mouse/B6C3F1/N

C Number:

Study Gender:

PWG Approval Date

M20V: Mixed Leukocyte Response Summary

Test Compound: Resveratrol

CAS Number: 501-36-0

IMM20704

Male

See web page for date of PWG Approval

Date Report Requested: 04/14/2020

Time Report Requested: 07:37:05

Lab: NTP

Study Number: IMM20704

Test Type: TOX

Route: Oral Gavage

Species/Strain: Mouse/B6C3F1/N

M20V: Mixed Leukocyte Response Summary

Test Compound: Resveratrol

CAS Number: 501-36-0

Date Report Requested: 04/14/2020

Time Report Requested: 07:37:05

Lab: NTP

Males: Study 4

Treatment Groups (mg/kg/day)

	0	156	312	625	1250	2500	50 mg/kg CPS
Responders (cpm)	342 ± 37 (8)	340 ± 57 (8)	368 ± 41 (8)	248 ± 33 (8)	428 ± 35 (7)	248 ± 24 (6)	219 ± 36 (8) *
Responders + Stimulators (cpm)	34285 ± 5808 (8)	28340 ± 4960 (8)	38678 ± 5525 (8)	23762 ± 7314 (8)	47642 ± 5675 (8)	18378 ± 5175 (6)	2363 ± 261 (7) **

Study Number: IMM20704

Test Type: TOX

Route: Oral Gavage

Species/Strain: Mouse/B6C3F1/N

M20V: Mixed Leukocyte Response Summary

Test Compound: Resveratrol

CAS Number: 501-36-0

Date Report Requested: 04/14/2020

Time Report Requested: 07:37:05

Lab: NTP

LEGEND

Data are displayed as mean \pm SEM (N) unless otherwise noted.

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Kruskal-Wallis test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

CPS = Cyclophosphamide

**** END OF REPORT ****